文献速递外周动脉疾病

紫杉醇涂层器械用于外周动脉疾病患者后的结局:一项全国性人群研究

Outcomes after Paclitaxel Coated Device Use in Patients with Peripheral Artery Disease: A Nationwide Population Based Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-02-08

该研究利用台湾全民健康保险研究数据库的行政医疗数据,开展全国性回顾性队列研究,纳入2016年5月至2019年12月接受下肢血管内血运重建的19612例患者。倾向性匹配队列分析显示,紫杉醇涂层器械(PCD)组全因死亡风险低于非PCD组(sHR 0.71,95%CI 0.64-0.78),复合心血管结局也更少(sHR 0.79,95%CI 0.71-0.88),复合肢体结局无差异(sHR 0.98,95%CI 0.89-1.08)。

要点

  • 中位随访14.2个月,PCD组全因死亡24.3%,非PCD组31.7%(sHR 0.71,95%CI 0.64-0.78)。
  • 复合心血管结局PCD组20.1%,对照组23.3%(sHR 0.79,95%CI 0.71-0.88)。
  • 复合肢体结局PCD组28.2%,非PCD组26.6%(sHR 0.98,95%CI 0.89-1.08)。

核心结论

  • 在接受血管内血运重建的患者中,使用PCD与较低的全因死亡风险和复合心血管结局风险相关,复合肢体结局无差异。

研究设计与样本

  • 全国性回顾性队列研究,使用台湾全民健康保险研究数据库的行政医疗数据,纳入2016年5月至2019年12月接受下肢血管内血运重建的19612例患者,在倾向性匹配队列中评估结局。

主要发现

  • 中位随访14.2个月,PCD组2205例中535例(24.3%)发生全因死亡,非PCD组4410例中1398例(31.7%)发生全因死亡(sHR 0.71,95%CI 0.64-0.78)。
  • 复合肢体结局PCD组622例(28.2%),非PCD组1174例(26.6%)(sHR 0.98,95%CI 0.89-1.08)。
  • 复合心血管结局PCD组20.1%,对照组23.3%(sHR 0.79,95%CI 0.71-0.88)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A summary level meta-analysis showed an increased mortality rate beyond the first year following revascularisation with paclitaxel coated devices (PCDs) in patients with peripheral artery disease. However, these findings remain controversial. This study aimed to provide a real world analysis on the safety of PCDs. METHODS: An exhaustive nationwide retrospective cohort study was conducted using administrative medical data from the National Health Insurance Research Database in Taiwan. A total of 19 612 patients receiving endovascular lower limb revascularisation from May 2016 to December 2019 were analysed. All cause death, limb outcome, and cardiovascular (CV) outcome in the propensity matched cohort were assessed. Limb outcome was the composite of new onset chronic limb threatening ischaemia or amputation. Cardiovascular outcomes included CV death, non-fatal ischaemic stroke, non-fatal myocardial infarction, or heart failure (HF) hospitalisation. RESULTS: Over a median of 14.2 months, all cause death occurred in 535 of 2 205 patients (24.3%) receiving PCDs and 1 398 of 4 410 (31.7%) receiving non-PCDs (subdistribution hazard ratio [sHR] 0.71, 95% confidence interval [CI] 0.64 - 0.78). The composite limb outcome occurred in 622 patients (28.2%) in the PCD group and in 1 174 patients (26.6%) in the non-PCD group (sHR 0.98, 95% CI 0.89 - 1.08). The composite CV outcome was less frequent in patients receiving PCD (20.1%) than control (23.3 %) (sHR 0.79, 95% CI 0.71 - 0.88). CONCLUSION: In patients having endovascular revascularisation, exposure to a PCD was associated with lower risk of all cause death and composite CV outcome. There was no difference in composite limb outcome.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Huang CY, Lee JK, Wu HP, et al. Outcomes after Paclitaxel Coated Device Use in Patients with Peripheral Artery Disease: A Nationwide Population Based Study. Eur J Vasc Endovasc Surg. 2025. PMID: 39929316. doi:10.1016/j.ejvs.2025.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。